Baird analyst Jeffrey Meuler upgrades Equifax (NYSE:EFX) from Neutral to Outperform and lowers the price target from $290 to $281.
Baird Upgrades Equifax to Outperform, Lowers Price Target to $281
Baird analyst Jeffrey Meuler upgrades Equifax (NYSE:EFX) from Neutral to Outperform and lowers the price target from $290 to $281.
Related Posts
Scientific Games Appoints Connie James As Finance Chief
Scientific Games Corp (NASDAQ:SGMS) has appointed Connie James as Executive Vice President, Chief Financial Officer, Treasurer, and Corporate Secretary, effective…
55 Biggest Movers From Friday
Gainers
Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 100.9% to close at $2.27 on Friday. Vallon Pharmaceuticals engaged Ladenburg Thalmann & Co Inc to evaluate strategic alternatives for the Company to maximize shareholder value.